CO6251368A2 - Derivados de (1)-2- dihidro-4h, 9h-imidazo[1, 2, 3-ij]-1, 8- naftiridina-4,9-diona o 1, 2-dihidro-3h, 8h-2a,5, 8a- triazaacenaphtileno-3, 8- diona utiles como antibacterianos - Google Patents

Derivados de (1)-2- dihidro-4h, 9h-imidazo[1, 2, 3-ij]-1, 8- naftiridina-4,9-diona o 1, 2-dihidro-3h, 8h-2a,5, 8a- triazaacenaphtileno-3, 8- diona utiles como antibacterianos

Info

Publication number
CO6251368A2
CO6251368A2 CO09116570A CO09116570A CO6251368A2 CO 6251368 A2 CO6251368 A2 CO 6251368A2 CO 09116570 A CO09116570 A CO 09116570A CO 09116570 A CO09116570 A CO 09116570A CO 6251368 A2 CO6251368 A2 CO 6251368A2
Authority
CO
Colombia
Prior art keywords
alkyl
dihidro
diona
hydrogen
substituted
Prior art date
Application number
CO09116570A
Other languages
English (en)
Inventor
David Evan Davies
David Thomas Davies
Llaria Giordano
Alan Joseph Hennessy
Neil David Pearson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39580226&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6251368(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0707705A external-priority patent/GB0707705D0/en
Priority claimed from GB0720569A external-priority patent/GB0720569D0/en
Priority claimed from GB0805311A external-priority patent/GB0805311D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO6251368A2 publication Critical patent/CO6251368A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1.- Un compuesto de fórmula (I) o una sal farmacéuticamente aceptable y/o N-óxido del mismo:en el que:Z1 y Z2 se seleccionan independientemente entre CH y N;R1a y R1b se seleccionan independientemente entre hidrógeno; halógeno; ciano; alquilo (C1-6); alquiltio (C1-6); trifluorometilo; trifluorometoxi; carboxi; hidroxi opcionalmente sustituido con alquilo (C1-6) o alcoxi (C1-6)-alquilo (C1-6) sustituido; alcoxi (C1-6)-alquilo (C1-6) sustituido; hidroxialquilo (C1-6); un grupo amino opcionalmente N-sustituido con uno o dos grupos alquilo (C1-6), formilo, alquil (C1-6) carbonilo o alquil (C1-6)-sulfonilo; y aminocarbonilo en donde el grupo amino está opcionalmente sustituido con alquilo (C1-4); con la condición de que R1a y R1b sean H cuando Z2 o Z1 es N, respectivamente; R2 es hidrógeno o alquilo (C1-4), o junto con R6 forma Y según se define a continuación; A es un grupo (i):donde: R3 es como se ha definido para R1a y R1b o es oxo y n es 1 ó 2: o A es un grupo (ii)W1, W2 y W3 son CR4R8o W2 y W3 son CR4R8 y W1 representa un enlace entre W3 y N.X es O, CR4R8, o NR6;un R4 es como se ha definido para R1a y R1b y el resto y R8 son hidrógeno o un R4 y R8 son juntos oxo y el resto son hidrógeno; ...
CO09116570A 2007-04-20 2009-10-19 Derivados de (1)-2- dihidro-4h, 9h-imidazo[1, 2, 3-ij]-1, 8- naftiridina-4,9-diona o 1, 2-dihidro-3h, 8h-2a,5, 8a- triazaacenaphtileno-3, 8- diona utiles como antibacterianos CO6251368A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0707705A GB0707705D0 (en) 2007-04-20 2007-04-20 Compounds
GB0720569A GB0720569D0 (en) 2007-10-19 2007-10-19 Compounds
GB0805311A GB0805311D0 (en) 2008-03-20 2008-03-20 Compounds

Publications (1)

Publication Number Publication Date
CO6251368A2 true CO6251368A2 (es) 2011-02-21

Family

ID=39580226

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09116570A CO6251368A2 (es) 2007-04-20 2009-10-19 Derivados de (1)-2- dihidro-4h, 9h-imidazo[1, 2, 3-ij]-1, 8- naftiridina-4,9-diona o 1, 2-dihidro-3h, 8h-2a,5, 8a- triazaacenaphtileno-3, 8- diona utiles como antibacterianos

Country Status (32)

Country Link
US (1) US8389524B2 (es)
EP (1) EP2137196B1 (es)
JP (1) JP5389013B2 (es)
KR (1) KR101567096B1 (es)
CN (1) CN101687887B (es)
AR (1) AR066111A1 (es)
AT (1) ATE483717T1 (es)
AU (1) AU2008240764C1 (es)
BR (1) BRPI0810064B8 (es)
CA (1) CA2684659C (es)
CL (1) CL2008001122A1 (es)
CO (1) CO6251368A2 (es)
CR (2) CR11123A (es)
CY (1) CY1111248T1 (es)
DE (1) DE602008002912D1 (es)
DK (1) DK2137196T3 (es)
DO (1) DOP2009000240A (es)
EA (1) EA015821B1 (es)
HK (1) HK1138000A1 (es)
HR (1) HRP20100574T1 (es)
IL (1) IL201204A0 (es)
MA (1) MA31324B1 (es)
MX (1) MX2009011317A (es)
MY (1) MY149347A (es)
NZ (1) NZ579877A (es)
PE (1) PE20090274A1 (es)
PL (1) PL2137196T3 (es)
PT (1) PT2137196E (es)
SI (1) SI2137196T1 (es)
TW (1) TWI431006B (es)
UY (1) UY31038A1 (es)
WO (1) WO2008128942A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2626641A1 (en) * 2005-10-21 2007-07-19 Glaxo Group Limited Compounds
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
GB0608263D0 (en) 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
EP2205609B1 (de) 2007-10-19 2017-03-29 Boehringer Ingelheim International GmbH Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
NZ585346A (en) 2007-10-19 2011-09-30 Boehringer Ingelheim Int Substituted piperidino-dihydrothienopyrimidines
US8486948B2 (en) 2007-10-19 2013-07-16 Boehringer Ingelheim International Gmbh Piperazinodihydrothienopyrimidine derivatives
US8349828B2 (en) 2008-02-20 2013-01-08 Actelion Pharmaceuticals Ltd. Azatricyclic antibiotic compounds
EP2300477A1 (en) * 2008-05-23 2011-03-30 Glaxo Group Limited Tricyclic nitrogen containing compounds and their use as antibacterials
KR20110016947A (ko) * 2008-05-23 2011-02-18 글락소 그룹 리미티드 트리시클릭 질소 함유 화합물 및 항박테리아제로서의 그의 용도
RU2530884C2 (ru) 2008-10-07 2014-10-20 Актелион Фармасьютиклз Лтд Трициклические оксазолидиноновые антибиотические соединения
JP2012505866A (ja) * 2008-10-17 2012-03-08 グラクソ グループ リミテッド 抗菌剤として使用される三環式窒素化合物
CA2749163A1 (en) 2009-01-14 2010-07-22 The Salk Institute For Biological Studies Methods for screening and compounds that protect against amyloid diseases
AR076222A1 (es) 2009-04-09 2011-05-26 Actelion Pharmaceuticals Ltd Derivados 2-hidroxietil-1h-quinolin-ona y sus analogos azaisotericos con actividad antibacteriana y composiciones farmaceuticas que los contienen
TW201130854A (en) 2009-12-22 2011-09-16 Bayer Schering Pharma Ag Pyridinone derivatives and pharmaceutical compositions thereof
EP2566329B1 (en) 2010-05-04 2020-09-09 Alkermes Pharma Ireland Limited Process for synthesizing oxidized lactam compounds
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
CN103113291B (zh) * 2013-02-04 2015-03-04 浙江大学 一种3位烯基吡啶衍生物的合成方法
JP6453216B2 (ja) * 2013-07-23 2019-01-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ縮合環化合物
SG11201700566SA (en) * 2014-08-22 2017-03-30 Glaxosmithkline Ip Dev Ltd Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection
MA45463A (fr) * 2016-06-22 2019-05-01 Univ Vanderbilt Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
CA3060545A1 (en) 2017-04-17 2018-10-25 Ohio State Innovation Foundation Type ii topoisomerase inhibitors and methods of making and using thereof
BR112021018815A2 (pt) 2019-04-03 2022-03-03 Glaxosmithkline Ip Dev Ltd Gepotidacina para uso no tratamento de infecções bacterianas do trato urinário
WO2021004910A1 (en) 2019-07-05 2021-01-14 Glaxosmithkline Intellectual Property Development Limited Combination for the treatment of infections caused by mycoplasma genitalium
EP4125905A1 (en) 2020-04-02 2023-02-08 GlaxoSmithKline Intellectual Property Development Limited Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
EP4143188A1 (en) * 2020-04-29 2023-03-08 GlaxoSmithKline Intellectual Property Development Limited Crystalline forms of gepotidacin
CN111494241B (zh) * 2020-06-01 2023-03-24 湖北洁世达环保科技有限公司 一种纸巾柔润保湿液
EP4288035A1 (en) 2021-02-05 2023-12-13 GlaxoSmithKline Intellectual Property Development Limited Oral solid dose formulations
CA3240991A1 (en) 2022-01-21 2023-07-27 Nicole SCANGARELLA-OMAN Gepotidacin and vancomycin for use in the treatment of an infection caused by staphylococcus saprophyticus
EP4316463A1 (en) 2022-08-02 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Novel formulation
WO2024068524A1 (en) 2022-09-26 2024-04-04 Glaxosmithkline Intellectual Property Development Limited Gepotidacin for use in the treatment of bacterial prostatitis

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403610B1 (en) 1999-09-17 2002-06-11 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them
US6525049B2 (en) 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
US6624159B2 (en) 2000-07-12 2003-09-23 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
PL366335A1 (en) 2000-07-26 2005-01-24 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
US6603005B2 (en) 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1345903A1 (en) 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6602884B2 (en) 2001-03-13 2003-08-05 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
EP1470131A2 (en) 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
TW200406413A (en) 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
ATE463494T1 (de) 2002-10-10 2010-04-15 Morphochem Ag Komb Chemie Neue verbindungen mit antibakterieller aktivität
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
ES2340484T3 (es) 2002-11-05 2010-06-04 Glaxo Group Limited Agentes antibacterianos.
TW200427688A (en) 2002-12-18 2004-12-16 Glaxo Group Ltd Antibacterial agents
TW200507841A (en) 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
US7232833B2 (en) 2003-03-28 2007-06-19 Novexel 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
WO2006002047A2 (en) 2004-06-15 2006-01-05 Glaxo Group Limited Antibacterial agents
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1773831A1 (en) 2004-07-08 2007-04-18 Glaxo Group Limited Antibacterial agents
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
JP2008507543A (ja) 2004-07-22 2008-03-13 グラクソ　グループ　リミテッド 抗細菌剤
WO2006017468A2 (en) 2004-08-02 2006-02-16 Glaxo Group Limited Antibacterial agents
JP2008509222A (ja) 2004-08-09 2008-03-27 グラクソ グループ リミテッド 抗菌剤
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
CA2580621A1 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
WO2006038172A1 (en) 2004-10-05 2006-04-13 Actelion Pharmaceuticals Ltd New piperidine antibiotics
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
WO2006081182A2 (en) 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
JP2008528604A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
JP2008528586A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
EP1845995A4 (en) 2005-01-25 2010-03-03 Glaxo Group Ltd ANTIBACTERIAL AGENTS
US7605169B2 (en) 2005-01-25 2009-10-20 Glaxo Group Limited Antibacterial agents
WO2006099884A1 (en) 2005-03-24 2006-09-28 Actelion Percurex Ag Beta-aminoalcohol antibiotics
US7842810B2 (en) 2005-03-31 2010-11-30 Janssen Pharmaceutica, Nv Bicyclic pyrazole compounds as antibacterial agents
MX2007014507A (es) 2005-05-24 2008-02-07 Astrazeneca Ab Aminopiperidin quinolinas y sus analogos azaisostericos con actividad antibacteriana.
JP2008542258A (ja) 2005-05-25 2008-11-27 アクテリオン ファーマシューティカルズ リミテッド 新規抗生物質誘導体
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
US8329694B2 (en) 2005-06-24 2012-12-11 Toyama Chemical Co., Ltd. Quinoxalinones as antibacterial composition
CA2626641A1 (en) * 2005-10-21 2007-07-19 Glaxo Group Limited Compounds
US20070185153A1 (en) 2005-12-22 2007-08-09 Nathalie Cailleau Compounds
ATE481406T1 (de) 2006-04-06 2010-10-15 Glaxo Group Ltd Pyrrolochinoxalinonderivate als antibakterielle mittel
JP2009532504A (ja) 2006-04-06 2009-09-10 グラクソ グループ リミテッド 抗菌薬
GB0608263D0 (en) * 2006-04-26 2006-06-07 Glaxo Group Ltd Compounds
JP2009539807A (ja) 2006-06-09 2009-11-19 グラクソ グループ リミテッド 抗菌薬としての置換１−メチル−１ｈ−キノリン−２−オンおよび１−メチル−１ｈ−１，５−ナフチリジン−２−オン
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
EP1992628A1 (en) 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
GB0705672D0 (en) * 2007-03-23 2007-05-02 Glaxo Group Ltd Compounds
EP1980251A1 (en) 2007-04-13 2008-10-15 Glaxo Group Limited Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis
GB0707708D0 (en) 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
GB0707706D0 (en) 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
EP2005995A1 (en) 2007-06-22 2008-12-24 Glaxo Group Limited Heterocyclic compounds for the treatment of tuberculosis
GB0800367D0 (en) 2008-01-09 2008-02-20 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
EA015821B1 (ru) 2011-12-30
NZ579877A (en) 2011-09-30
WO2008128942A1 (en) 2008-10-30
PT2137196E (pt) 2010-12-16
CN101687887A (zh) 2010-03-31
HRP20100574T1 (hr) 2010-12-31
TW200848420A (en) 2008-12-16
AU2008240764A1 (en) 2008-10-30
CA2684659A1 (en) 2008-10-30
CR20150586A (es) 2016-04-04
US8389524B2 (en) 2013-03-05
JP2010524884A (ja) 2010-07-22
BRPI0810064B1 (pt) 2021-03-30
JP5389013B2 (ja) 2014-01-15
CA2684659C (en) 2015-11-24
IL201204A0 (en) 2010-05-17
AU2008240764C1 (en) 2011-10-20
CL2008001122A1 (es) 2008-10-24
KR101567096B1 (ko) 2015-11-06
MA31324B1 (fr) 2010-04-01
KR20100017133A (ko) 2010-02-16
DOP2009000240A (es) 2009-12-31
DE602008002912D1 (de) 2010-11-18
EA200970987A1 (ru) 2010-04-30
TWI431006B (zh) 2014-03-21
BRPI0810064A2 (pt) 2019-08-27
CY1111248T1 (el) 2015-06-11
EP2137196B1 (en) 2010-10-06
PE20090274A1 (es) 2009-04-03
UY31038A1 (es) 2008-11-28
SI2137196T1 (sl) 2011-01-31
AR066111A1 (es) 2009-07-22
ATE483717T1 (de) 2010-10-15
BRPI0810064B8 (pt) 2021-05-25
EP2137196A1 (en) 2009-12-30
HK1138000A1 (en) 2010-08-13
US20100137282A1 (en) 2010-06-03
MX2009011317A (es) 2009-11-05
AU2008240764B2 (en) 2011-04-07
DK2137196T3 (da) 2011-01-10
MY149347A (en) 2013-08-30
PL2137196T3 (pl) 2011-03-31
CR11123A (es) 2010-03-08
CN101687887B (zh) 2012-08-29

Similar Documents

Publication Publication Date Title
CO6251368A2 (es) Derivados de (1)-2- dihidro-4h, 9h-imidazo[1, 2, 3-ij]-1, 8- naftiridina-4,9-diona o 1, 2-dihidro-3h, 8h-2a,5, 8a- triazaacenaphtileno-3, 8- diona utiles como antibacterianos
MX2011011875A (es) Compuesto de carboxamida heterociclica diamino.
CR10383A (es) Derivados triazolopirazina.
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR087288A1 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MX2009004426A (es) Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores alk y c-met.
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
AR078270A1 (es) Inhibidores de jak (quinasas janus)
AR049770A1 (es) Derivados de piperidina como moduladores de la actividad de quimioquinas
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR058587A1 (es) Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos
PE20080182A1 (es) Derivados pirrolo-quinoxalinona como antibacterianos
CO6190513A2 (es) Compuestos tetrahidrociclopenta [b] indol como moduladores del receptor de androgenos
HK1138262A1 (en) Novel phosphodiesterase inhibitors
MX2014015669A (es) Derivados de 2-aminopirazina como inhibidores de cinasa receptor del factor estimulador de colonias-1 (csf-1r).
TW200634013A (en) Quinoline derivative, its use, production and pharmaceutical agents containing the derivative
ECSP10010303A (es) (dihidro)pirrolo[2,1-a]isoquinolinas
PH12015500009B1 (en) Phenoxyethyl piperidine compounds
AR065583A1 (es) Compuestos macrociclicos y composicion farmaceutica

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed